26 September 2024
26 September 2024
OXBRYTA had been authorised in more than 35 countries across the globe.
The funds will advance Genespire’s gene therapy for methylmalonic acidemia, a group of rare metabolic disorders, to Phase I/II trials.
The companies will focus on developing new assets to treat liver diseases.
The tracker, currently available via a pilot scheme, could save pharmacists hours by reducing patient queries.
Lord Darzi’s independent report of the NHS and the Labour conference in Liverpool got leaders at HETT 2024 to discuss the UKs healthcare sector.
Aitia is entitled to receive milestone payments exceeding $10m per drug target.
A humanised monoclonal antibody, KEYTRUDA can enhance the immune system's potential to detect and combat tumour cells.
Epigenetic drugs induce heritable modifications to genetic material that result in changes in gene expression without altering the DNA sequence.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
